In the United States, approximately 60-70% of women with advanced breast cancer (aBC) are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) [1–3]. This evidence concerns the gene ERBB2 and breast carcinoma.